Frank Torti serves as President and Vant Chair at Roivant Sciences Ltd., where he leads the strategic oversight and operational execution across the company’s portfolio of innovative subsidiaries, or Vants. In this role, he drives the development of novel therapies in areas such as immunology, oncology, and rare diseases, leveraging Roivant’s unique model of agile, technology-enabled drug development to accelerate timelines from discovery to commercialization. His leadership emphasizes efficient capital allocation and cross-functional collaboration to address unmet medical needs. With a background spanning over two decades in biotechnology and venture capital, Torti previously held executive positions at several life sciences firms, where he focused on clinical-stage asset advancement and strategic partnerships. He has contributed to multiple successful drug approvals and company exits, building expertise in translational medicine and regulatory strategy that has informed his approach at Roivant. Torti’s achievements include guiding high-impact investments and fostering environments that have produced breakthrough candidates now in late-stage trials. His work at Roivant continues to position the company as a pioneer in reimagining pharmaceutical R&D through data-driven decision-making and entrepreneurial subsidiary structures.